Treatment of glioma cells with Michael acceptors–TrxR1 inhibitors 5 and 6 induced a significant increase in GSTπ expression, presumably as a defense mechanism against applied xenobiotics. The gene discussed is TXNRD1; the disease is central nervous system cancer.